InflaRx Announces Participation in September Investor Conferences
Rhea-AI Summary
InflaRx (Nasdaq: IFRX) announced its participation in two investor conferences in September 2026 in New York.
At the Cantor Global Healthcare Conference 2026, the company will join a fireside chat on September 9, 2026 at 3:20 PM ET and hold one-on-one investor meetings the same day. A live and replay link will be made available online.
At the H.C. Wainwright 28th Annual Global Investment Conference, InflaRx will present on September 14, 2026 at 10:00 AM ET and also conduct one-on-one meetings, with registration and replay access provided via an online link.
Positive
- None.
Negative
- None.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Aug 06 | 2Q26 earnings report | Positive | -2.8% | Reported improved loss, expanded funding runway, and strategic focus on izicopan. |
| Jul 30 | Earnings date announcement | Neutral | +4.2% | Scheduled second-quarter financial and operating results release for August 6. |
| Jun 30 | AAV strategy update | Positive | -1.8% | Assessed broader European vasculitis strategy following EMA recommendation on Tavneos. |
| May 08 | Share offering closing | Negative | -2.6% | Closed $150 million underwritten offering of 75 million ordinary shares. |
| May 06 | Share offering pricing | Negative | +26.9% | Priced 75 million ordinary shares at $2.00 per share. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent six-month history showed more divergences than alignments, including negative reactions after the August 6 earnings and June 30 strategy updates.
Key Terms
complement system medical
c5a medical
c5ar medical
pk/pd medical
monoclonal antibody medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Jena, Germany, Aug. 20, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced it will participate in two investor conferences in September 2026. Details are as follows:
Cantor Global Healthcare Conference 2026
September 9 - 11, 2026 in New York, NY
Fireside chat on September 9th at 3:20 PM ET
InflaRx will also conduct one-on-one investor meetings on September 9th. A link to view the fireside chat live stream and its replay will become available here in the coming days.
H.C. Wainwright 28th Annual Global Investment Conference
September 14 - 16, 2026 in New York, NY
Presentation on September 14th at 10:00 AM ET
InflaRx will also conduct one-on-one investor meetings on September 14th. A link to register for the presentation live stream and its replay is available here.
About InflaRx
InflaRx (Nasdaq: IFRX) is a biopharmaceutical company pioneering anti-inflammatory therapeutics by applying its proprietary anti-C5a and anti-C5aR technologies to discover, develop and commercialize highly potent and specific inhibitors of the complement activation factor C5a and its receptor, C5aR. C5a is a powerful inflammatory mediator involved in the progression of a wide variety of inflammatory diseases. InflaRx‘s lead program is izicopan, an orally administered small molecule inhibitor of C5a-induced signaling via the C5a receptor, which has shown promising PK/PD characteristics as well as therapeutic potential in Phase 1 and Phase 2a clinical studies. The Company is developing izicopan for the treatment of ANCA-associated vasculitis and additional renal diseases. InflaRx also has developed vilobelimab, a novel, intravenously delivered, first-in-class, anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical studies.
InflaRx was founded in 2007, and the group has offices and subsidiaries in Jena and Munich, Germany, as well as Ann Arbor, MI, USA. For further information, please visit www.inflarx.de. Follow InflaRx on LinkedIn. InflaRx GmbH (Germany) and InflaRx Pharmaceuticals Inc. (USA) are wholly owned subsidiaries of InflaRx N.V. (together, InflaRx).
Contacts:
| InflaRx N.V. | MC Services AG |
| Jan Medina, CFA Vice President, Head of Investor Relations Email: IR@inflarx.de | Katja Arnold, Laurie Doyle, Dr. Regina Lutz Email: inflarx@mc-services.eu Europe: +49 89-210 2280 U.S.: +1-339-832-0752 |
FORWARD-LOOKING STATEMENTS
This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “estimate,” “believe,” “predict,” “potential” or “continue,” among others. Forward-looking statements appear in a number of places throughout this release and may include statements regarding our intentions, beliefs, projections, outlook, analyses, current expectations and the risks, uncertainties and other factors described under the heading “Risk Factors” and “Cautionary statement regarding forward looking statements” in our periodic filings with the SEC. These statements speak only as of the date of this press release and involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information becomes available in the future, except as required by law.
